Cell-Penetrating Peptide Conjugated to Methylene Blue Enhances Cancer Photodynamic Therapy | Research

The takeaway

Conjugating methylene blue to a cell-penetrating peptide (protamine) improved cellular uptake and lysosome targeting, enhancing photodynamic therapy efficacy against cancer cells.

Enhanced PDT with CPP delivery
Protamine CPP conjugation improved methylene blue uptake and lysosome targeting for more effective cancer photodynamic therapy

What the researchers found

CPP-methylene blue conjugates showed enhanced cellular uptake, lysosomal localization, and improved photodynamic therapy efficacy against cancer cells compared to unconjugated methylene blue.

Why it matters

Photodynamic therapy is limited by poor photosensitizer uptake into cancer cells. CPP conjugation could overcome this barrier, making PDT a more effective cancer treatment option.

The numbers in context

MB-Pro localized to lysosomes; induced necrosis vs apoptosis with MB alone

How the study worked

Conjugated protamine CPP with methylene blue via chemical coupling, purified by FPLC. Tested cellular uptake, subcellular localization, and PDT efficacy in cancer cell lines in vitro.

Who was studied

Colon cancer cell line (MCF-7 referenced but study focused on colon cancer cells)

What this study cannot tell us

In vitro study only — no in vivo tumor PDT data. Light penetration limits PDT to superficial or accessible tumors. Selectivity for cancer over normal cells not fully characterized.

How to read the evidence

Preliminary — in vitro proof of concept demonstrating enhanced PDT with CPP delivery; no animal or clinical data.

When this study was published

Published in 2020; CPP-photosensitizer conjugates remain an active area of cancer PDT research.

The bigger picture

This work demonstrates the versatility of cell-penetrating peptides as delivery vehicles beyond traditional drugs — here carrying a photosensitizer to enable light-activated cancer treatment.

Questions still open

Would CPP-MB conjugates show selective tumor accumulation in vivo?
Can this approach be combined with checkpoint immunotherapy for enhanced anti-tumor effects?
How does the PDT efficacy compare to established photosensitizers used clinically?

Common questions

What is photodynamic therapy?

PDT uses a light-sensitive drug (photosensitizer) that accumulates in cancer cells. When activated by specific wavelength light, it produces reactive oxygen species that kill the cancer cells while sparing unirradiated tissue.

Why attach a cell-penetrating peptide to the photosensitizer?

Photosensitizers like methylene blue often cannot efficiently enter cancer cells on their own. The CPP acts as a delivery vehicle, carrying the photosensitizer inside cells and directing it to lysosomes, where PDT-generated damage is most lethal.

Read the original research

Enhanced Efficacy of Photodynamic Therapy by Coupling a Cell-Penetrating Peptide with Methylene Blue.

International journal of nanomedicine, 15, 5803-5811

View on PubMed ↗Publisher’s paper ↗

Citation

Ser, Jinhui; Lee, Ji Yeon; Kim, Yong Ho; Cho, Hoonsung. (2020). Enhanced Efficacy of Photodynamic Therapy by Coupling a Cell-Penetrating Peptide with Methylene Blue.. International journal of nanomedicine, 15, 5803-5811. https://doi.org/10.2147/IJN.S254881